U.S. Markets closed

NuVasive, Inc. (NUVA)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
79.920-1.190 (-1.467%)
At close: 4:00PM EDT
People also watch
WMGIOFIXPODDNXTMMASI

NuVasive, Inc.

7475 Lusk Boulevard
San Diego, CA 92121
United States
858-909-1800
http://www.nuvasive.com

SectorHealthcare
IndustryMedical Appliances & Equipment
Full Time Employees1,900

Key Executives

NameTitlePayExercisedAge
Mr. Gregory T. LucierChairman and Chief Exec. Officer1.92MN/A53
Mr. Jason M. Hannon Esq.Pres and Chief Operating Officer2.03M3.2M45
Mr. Quentin S. BlackfordChief Financial Officer, Head of Strategy & Corp. Integrity and Exec. VP891.61kN/A38
Mr. Matthew W. LinkPres of US Commercial931.03kN/A42
Mr. Edmund J. RoschakChief Exec. Officer of Nuvasive Specialized Orthopedics Inc3.08MN/A50
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NuVasive, Inc., a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including biologics used for spinal fusion process. The company’s principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, NVM5, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable surgeons access to the spine and to perform restorative and fusion procedures in a minimally-disruptive fashion. Its biologics products include Osteocel Plus and Pro, a cellular bone matrix; Formagraft, a collagen-based synthetic bone substitute; AttraX, a synthetic bone graft material; and Propel DBM, a moldable demineralized bone matrix putty, which are used for spinal fusion or bone healing process. The company’s IOM services are used for onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. It also provides implants; and fixation products, including pedicle screws, rods, and plates. In addition, the company offers Integrated Global Alignment platform for assessing, preserving, and restoring spinal alignment; MAGEC-early onset scoliosis, a spinal bracing and distraction system; and PRECICE, a limb lengthening system. NuVasive, Inc. sells its products to hospitals, surgeons, and other customers through independent sales agents, directly-employed sales personnel, and distributors in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.

Corporate Governance

NuVasive, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.